Pazopanib in sarcomas
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference30 articles.
1. The B-Raf status of tumor cells may be a significant determinant of both antitumor and antiangiogenic effects of pazopanib in xenograft tumor models.;Gril;PLoS One,2011
2. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.;Kumar;Mol Cancer Ther,2007
3. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.;Sternberg;J Clin Oncol,2010
4. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.;Bible;Lancet Oncol,2010
5. Pazopanib: clinical development of a potent antiangiogenic drug.;Schutz;Crit Rev Oncol Hematol,2011
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and efficacy of fruquintinib‐based therapy in patients with advanced or metastatic sarcoma;Cancer Medicine;2024-07
2. A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety;Cancers;2023-12-30
3. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16
4. A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma;Gynecologic Oncology Reports;2023-02
5. Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution;Cancer Management and Research;2020-03
Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3